Inclusion Criteria:

- Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with
metastasis to soft tissue and/or bone; responsive stage IV disease is defined as
patients who achieve a PR (>= 50% reduction in measurable tumor burden) or CR
following initial chemotherapy for metastatic disease or patients with locally
recurrent disease (chest wall/axillary nodes) who are rendered disease-free following
surgery or radiation therapy without receiving chemotherapy; bone disease is
categorized as responsive if there is demonstrated sclerosis of prior lesions with no
new lesions

- Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen
for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes)
patients rendered NED by RT or surgery do not need to receive chemotherapy for stage
IV disease prior to Cytoxan/Taxol

- Patient has received Cytoxan 4 gm/m^2 x 1 and Taxol 250 mg/m^2 x 1 per FHCRC protocol
506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and
before transplant

- Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization
from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were
collected by using G-CSF according to FHCRC protocol 753; patient has an adequate
number of peripheral blood stem cells stored (>= 2.5 x 10^6 CD34+ cells/kg)

- The patient must have the capacity to give informed consent; the patient must have
signed an approved consent form conforming with federal and institutional guidelines

- Hepatic function: Bilirubin =< 2 mg%; SGOT or SGPT =< 2.5 x institutional normal

- Renal function: Creatinine =< 2.0 mg/dl or a creatinine clearance >= 50 mg/min

- Pre-Study tests have been performed as outlined in the Study Calendar

- Patients will begin IL-2/GM-CSF therapy if they meet the following criteria
post-transplant:

- Can start therapy 30 to 100 days after transplant

- Karnofsky performance status > 60

- ANC > 1,000 cells/mm^3 and platelets > 30,000/cells/mm^3 (transfusion independent)
for at least 5 days before starting therapy

- Total bilirubin =< 2.5 x upper limit of normal

- SGOT =< 2.5 x upper limit of normal

- Creatinine =< 2.0 mg/dl

Exclusion Criteria:

- Patients with a Karnofsky Performance Score less than 70

- Patients with a left ventricular ejection fraction less than 50 % (LVEF must be
performed in patients with symptoms of CHF, abnormal cardiac exam or history of
Adriamycin therapy total dose > 400 mg/m^2)

- Patient is pregnant

- Patient is seropositive for the human immunodeficiency virus

- Patients with a history of seizures

- Patients with hypersensitivity to E.coli preparations

- Patients with active auto-immune disease

- Patients with clinically significant pulmonary disease, i.e., diffusion capacity
corrected < 60% of predicted; patients with pulmonary problems should be evaluated
with appropriate pulmonary studies and/or consult

- Patients with a history of CNS lesion (brain or carcinoid meningitis)

- Patients with significant active infection precluding transplant

- Patients who have had more than one prior chemotherapy regimen for stage IV disease
or a prior transplant for any stage disease

- Patients who have had CD34+ selection of their PBSC products

- Patients will not receive IL-2/GM-CSF therapy if they:

- Are > 100 days from transplant

- Have documented disease progression after transplant

- Have an active infection

- Manifested cardiac complications during the initial transplant period, including
arrhythmias (that required therapy), congestive heart failure, angina, myocardial
infarct, or decreased LVEF to < 45%

- Currently have pericardial effusions, pleural effusions or ascites

- Manifested pulmonary toxicity during the initial transplant period and have a
diffusion capacity corrected =< 60%

- Are on steroids

- Currently have a Grade 3 toxicity from BuMelTT

- If the patient does not wish to receive the therapy